Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions
Clinical trial NCT06561087 · RECRUITING
Trial details
- NCT number
- NCT06561087
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-27
- Primary completion
- 2027-05-30
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.